CD133 expression associated with poor prognosis in ovarian cancer

Modern Pathology

Volumn 25, Issue 3, 2012, Pages 456-464

  Zhang, Jing ^a,b   Guo, Xiaoqing ^a,c   Chang, Doo Young ^a,d   Rosen, Daniel G ^a   Mercado Uribe, Imelda ^a   Liu, Jinsong ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c SHIHEZI UNIVERSITY   (China)

^d Inje University College of Medicine   (South Korea)

Author keywords

CD133; immunohistochemistry; ovarian cancer; prognosis

Indexed keywords

CD133 ANTIGEN; CISPLATIN; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER STEM CELL; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FISHER EXACT TEST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS OF COVARIANCE; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEROSA; SURVIVAL TIME; TISSUE MICROARRAY; TREATMENT RESPONSE;

EID: 84857790077     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.170     Document Type: Article

References (47)

1. Reya T,Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
2. O'Brien CA, Kreso A, Jamieson CH. Cancer stem cells and self-renewal. Clin Cancer Res 2010;16: 3113-3120.
3. Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 2010;102:1276-1283.
4. Bertrand J, Begaud-Grimaud G, Bessette B, et al. Cancer stem cells from human glioma cell line are resistant to Fas-induced apoptosis. Int J Oncol 2009;34:717-727.
5. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
6. Curley MD, Garrett LA, Schorge JO, et al. Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Front Biosci 2011;16:368-392.
7. Miraglia S, Godfrey W, Yin AH, et al. A novel fivetransmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997;90:5013-5021.
8. Neuzil J, Stantic M, Zobalova R, et al. Tumourinitiating cells vs. cancer 'stem' cells and CD133: what's in the name? Biochem Biophys Res Commun 2007;355:855-859.
9. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-5012.
10. Al Dhaybi R, Sartelet H, Powell J, et al. Expression of CD133+ cancer stem cells in childhood malignant melanoma and its correlation with metastasis. Mod Pathol 2010;23:376-380.
11. Pallini R, Ricci-Vitiani L, Montano N, et al. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer 2011;117:162-174.
12. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504-514.
13. Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:2542-2556.
14. Wei C, Guomin W, Yujun L, et al. Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line? Cancer Biol Ther 2007;6: 763-768.
15. Horst D, Scheel SK, Liebmann S, et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 2009;219:427-434.
16. Wright MH, Calcagno AM, Salcido CD, et al. Brca1 breast tumors contain distinct CD44 +CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008;10:R10.
17. Baba T, Convery PA, Matsumura N, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009;28:209-218.
18. Guo R, Wu Q, Liu F, et al. Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3. Oncol Rep 2010;25:141-146.
19. Curley MD, Therrien VA, Cummings CL, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009;27:2875-2883.
20. Ma L, Lai D, Liu T, et al. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochim Biophys Sin (Shanghai) 2010;42:593-602.
21. Scully RE. World Health Organization classification and nomenclature of ovarian cancer. Natl Cancer Inst Monogr 1975;42:5-7.
22. Russell P. The pathological assessment of ovarian neoplasms. I: introduction to the common epithelial tumours and analysis of benign epithelial tumours. Pathology 1979;11:5-26.
23. Russell P. The pathological assessment of ovarian neoplasms. II: the proliferating epithelial tumours. Pathology 1979;11:251-282.
24. Russell P. The pathological assessment of ovarian neoplasms. III: the malignant epithelial tumours. Pathology 1979;11:493-532.
25. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004;28:496-504.
26. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989;96:889-892.
27. Rustin GJ, Nelstrop AE, Crawford M, et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. J Clin Oncol 1997;15:172-176.
28. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002;7:20-28.
29. Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 1996;7:361-364.
30. Rosen DG, Yang G, Deavers MT, et al. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 2006;106:1925-1932.
31. Sladek NE. Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol 2003;17:7-23.
32. Chang B, Liu G, Xue F, et al. ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol 2009;22:817-823.
33. Birnie R, Bryce SD, Roome C, et al. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol 2008; 9:R83.
34. Di Fiore R, Santulli A, Ferrante RD, et al. Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment. J Cell Physiol 2009;219:301-313.
35. Tagscherer KE, Fassl A, Campos B, et al. Apoptosisbased treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 2008;27:6646-6656.
36. Sussman RT, Ricci MS, Hart LS, et al. Chemotherapyresistant sidepopulation of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol Ther 2007;6:1490-1495.
37. Ferrandina G, Bonanno G, Pierelli L, et al. Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer 2008;18:506-514.
38. Ferrandina G, Martinelli E, Petrillo M, et al. CD133 antigen expression in ovarian cancer. BMC Cancer 2009;9:221.
39. Song W, Li H, Tao K, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008;62:1212-1218.
40. Sasaki A, Kamiyama T, Yokoo H, et al. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Rep 2010;24:537-546.
41. Li CY, Li BX, Liang Y, et al. Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med 2009;7:56.
42. Kojima M, Ishii G, Atsumi N, et al. CD133 expression in rectal cancer after preoperative chemoradiotherapy. Cancer Sci 2010;101:906-912.
43. Zhao P, Lu Y, Jiang X, et al. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci 2011; 102:1107-1111.
44. Zeppernick F, Ahmadi R, Campos B, et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008;14:123-129.
45. Xu YH, Zhang GB, Wang JM, et al. B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis. Saudi Med J 2010;31:980-986.
46. Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 2008;27:1-9.
47. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008;26:5284-5293.